Skip to content

Glioma: Biomolecular Aspects

Glioma: BIOMOLECULAR Aspects From Tissue to Radiomics

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05806619
Acronym
GLIOMA
Enrollment
150
Registered
2023-04-10
Start date
2019-10-22
Completion date
2022-09-30
Last updated
2023-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioma, Malignant

Brief summary

Main limitations in Glioma studies are due to the wide heterogeneity and genetic instability of the tumor and to the fact that the molecular informations are static, i.e. obtained on the tumor at its onset. Instead, spontaneous or therapy-induced variations are difficult to evaluate and they would need further sampling of the tumor throughout the clinical history. Currently these data are more and more routinely used not only for diagnostics but also in the clinical management of the patient. Furthermore, microenvironment study is becoming increasingly important. It is also important correlate morpho-functional pathway and brain Magnetic Resonance. Therefore, the main goal of the study is to correlate the data obtained with morphological (site, signal intensity, margins, behavior after contrast medium infusion, mismatch between T2 and FLAIR sequences) and non-morphological MR imaging through a radiomic approach and Diffusion and Perfusion study, with molecular data relating to the IDH mutation, MGMT gene promoter methylation, 1p/19q co-deletion and EGFRvIII expression. Furthermore, it is proposed to carry out a correlation between the radiological data and the mutations found in the NGS panel.

Interventions

OTHERhistopathological analysis; morphological and non-morphological magnetic resonance

The surgical material removed during surgery was subjected to histological analysis. Morphological and non-morphological magnetic resonance examination before the neurosurgical surgery, according to clinical practice.

Sponsors

Regina Elena Cancer Institute
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* glioma diagnosis * have performed morphological brain MRI or not with contrast medium before surgery * informed consent form

Exclusion criteria

* Patients without Magnetic Resonance were excluded

Design outcomes

Primary

MeasureTime frameDescription
Correlation between MR and molecular data24 monthsDemonstrate the existence of a correlation between the non-morphological brain Magnetic Resonance (MR) data obtained with diffusion and perfusion techniques and molecular data, in particular with MGMT gene methylation.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026